XRPTurbo Presale Nears 100,000 XRP Milestone as Investor Interest Surges Amid Market Volatility
TALLINN, Estonia, March 17, 2025 (GLOBE NEWSWIRE) -- XRPTurbo, a Web3 launchpad built on the XRP Ledger (XRPL), is on the verge of reaching a key milestone, with its ongoing presale approaching 100,000 XRP raised. This milestone comes amid recent market fluctuations in XRP's price, prompting investors to explore new opportunities within the XRPL ecosystem. XRPTurbo's rapid fundraising success highlights growing confidence in its innovative suite of decentralized finance (DeFi) tools and AI-driven solutions.
XRPTurbo Gains Momentum Amid XRP Volatility
XRPTurbo, an innovative Web3 launchpad built specifically for the XRP Ledger (XRPL), has quickly captured investor attention.
The presale has already crossed 90,000 XRP raised, demonstrating strong confidence and increasing momentum from the XRP community. Given the rapid rate at which funds are pouring in, analysts suggest XRPTurbo could soon cross the notable 100,000 XRP mark.
[ Join Xrpturbo Presale ]
This milestone comes at a pivotal moment as XRP navigates regulatory uncertainties and volatile price movements. XRP investors, seeking promising alternatives and secure growth opportunities within the ecosystem, have flocked to XRPTurbo, highlighting the project's growing appeal.
Why XRPTurbo Is Turning Heads Among XRP Investors
XRPTurbo offers XRP investors more than speculative potential—it presents genuine utility and innovation designed specifically for the XRP blockchain.
At the core of XRPTurbo's appeal is its impressive suite of decentralized tools and platforms developed to simplify and enhance decentralized finance (DeFi) within the Ripple ecosystem.
Among the standout tools being developed include:
A User-Friendly GUI Token & NFT Minting Platform: Allowing seamless creation of XRPL-native tokens and NFTs without technical complexity, this intuitive platform opens decentralized finance to broader audiences.
Advanced Token Locking & Vesting DApp: Essential for blockchain startups, this application offers secure token vesting mechanisms, helping projects build investor trust, foster transparency, and promote sustainable tokenomics.
AI Agent Creator: Integrating artificial intelligence with blockchain technology, XRPTurbo's AI agents provide advanced automation of smart contracts, trading strategies, data analytics, and social media management.
This comprehensive ecosystem positions XRPTurbo as the backbone of a new wave of DeFi innovation on XRPL, promising exponential growth in adoption and use cases.
[ Buy $XRT Tokens ]
XRT Token—At The Heart Of XRPTurbo's Ecosystem
The XRPTurbo platform is fueled by the native utility token, $XRT. With a capped maximum supply of 100 million tokens, XRT ensures token scarcity and potential long-term appreciation.
Holders of $XRT enjoy multiple exclusive advantages like:
Priority Access: Holders receive early entry into upcoming high-value AI and real-world asset (RWA) tokenization projects.
Revenue Sharing & Staking Rewards: Investors staking $XRT will benefit from future revenue-sharing mechanisms derived from platform fees.
Platform Utility: All platform fees—including minting, locking, vesting, and AI agent services—will be payable exclusively with XRT tokens, continually driving demand.
Notably, XRPTurbo has confirmed that the XRT token will list on decentralized exchanges at a price 25% higher than the final presale valuation, presenting immediate upside potential for early backers.
Click Here To Join Xrpturbo Presale ]
XRPTurbo is already in advanced talks with three leading crypto exchanges, planning swift listings following the conclusion of the presale. Early investors stand to benefit significantly as the increased liquidity and exposure from these listings could propel the $XRT token to new highs shortly after the launch.
Moreover, to further excite and build investor confidence, the XRPTurbo team is set to unveil an exclusive first look at the launchpad platform in the coming weeks, offering a glimpse into the intuitive interfaces and powerful tools soon to be available to users.
How Investors Can Join XRPTurbo's Presale
The ongoing presale offers XRP investors a unique, time-sensitive chance to acquire XRT tokens at the most competitive pricing. Given the escalating interest and rapid milestone achievements, analysts anticipate the presale will conclude ahead of schedule. Investors looking to benefit from early-stage pricing must act quickly as interested investors can participate by visiting XRPTurbo's official presale website at xrpturbo.com/presale.
Whitepaper: docs.xrpturbo.com
X (Twitter): x.com/xrpturbocom
Contact:
John Rodi
Disclaimer: This press release is provided by XRPTurbo. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining related opportunities involves significant risks, including the potential loss of capital. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector--including cryptocurrency, NFTs, and mining--complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Wedding Expert Jessica Bishop to Host Free Virtual Savvy Weddings Summit
Murfreesboro, TN, June 06, 2025 (GLOBE NEWSWIRE) -- Murfreesboro, TN. – Jessica Bishop, a nationally recognized wedding expert and founder of The Budget Savvy Bride, is hosting a free virtual wedding summit on June 21-22, designed to help engaged couples confidently plan a wedding that reflects their values — without overspending or unnecessary stress. At a time when wedding planning can often feel overwhelming and financially daunting, The Savvy Weddings Summit aims to simplify the process and empower couples with accessible, expert-led guidance. From navigating budgets and managing logistics to creating a celebration that is both meaningful and manageable, the summit delivers practical, actionable advice — not just pretty inspiration. 'So many couples feel pressured to create a 'Pinterest-perfect' wedding they can't afford, or they simply don't know where to start,' said Bishop. 'This summit is about giving couples the tools and confidence to plan intentionally, in alignment with their priorities — not the industry's expectations.' Bishop, a seasoned voice in the wedding industry, created the summit to democratize access to expert advice, ensuring that couples can achieve their ideal celebration regardless of their budget constraints. Attendees of The Savvy Weddings Summit will gain valuable insights into various aspects of wedding planning, from smart budgeting strategies to vendor selection, decor, and timeline management. The expert-led sessions are curated to provide actionable advice that couples can immediately apply to their planning process. All registered attendees will also receive access to a virtual goodie bag with exclusive discounts from various wedding brands, including summit sponsors Miss to Mrs Box and Something Borrowed Blooms. As an added incentive, all attendees who register for the free virtual summit will be entered to win prizes, including a dream honeymoon! This grand prize package includes airfare credit and ground transportation, offering a significant opportunity for a newlywed couple to celebrate their marriage in paradise! Register today for your chance to win a dream honeymoon to Mexico! Enter now at for a chance to win the grand prize: a 4-night Island Reserve Inclusive® stay for two adults at Margaritaville Island Reserve Riviera Maya, including round-trip Airfare credit (up to $500 per person) and airport from Jessica Bishop Jessica Bishop founded The Budget Savvy Bride with the mission to prove that beautiful, meaningful weddings are achievable on any budget. Her platform has become a trusted resource for millions of couples seeking practical advice and inspiration for affordable wedding planning. The Savvy Weddings Summit is a direct extension of this mission, bringing together a community of experts to support couples on their journey, democratizing access to expert advice, especially for couples who may not have the budget for a full-service wedding planner. The virtual format of the summit ensures accessibility for couples nationwide, allowing them to participate from the comfort of their homes. This flexible approach caters to busy schedules, making expert wedding planning advice more attainable. Couples interested in planning their dream wedding without financial strain are encouraged to register for the free virtual Savvy Weddings Summit. Detailed information about the summit, including the full schedule of sessions, speaker lineup, and registration details for the Mexico honeymoon giveaway, is available at About The Budget Savvy BrideJessica Bishop is a budget wedding expert, a best-selling author, and the founder of The Budget Savvy Bride, an extensive online resource to help couples plan a beautiful wedding on a budget they can actually afford. Jessica has shared her money-saving tips and planning advice with outlets such as The New York Times, Washington Post, GMA, BRIDES, Refinery 29, Glamour, Cosmopolitan, Huffington Post, and more. Jessica is also the host of The Bouquet Toss: Wedding Planning Podcast. Her book, The Budget-Savvy Wedding Planner & Organizer, is an Amazon best-seller, with over 250,000 copies sold! CONTACT: Heather Holmes heather@ 1+(828)332-5307
Yahoo
25 minutes ago
- Yahoo
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ('Keros') (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ('TGF-ß') family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 a.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at and an archived replay will be accessible in the Investors section of the Keros website at for up to 90 days following the conclusion of the event. About Keros Therapeutics, is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with an initial focus on Duchenne muscular dystrophy. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Investor Contact:Justin Frantzjfrantz@ 617-221-6042 Media Contact:Mahmoud Siddig / Adam Pollack / Viveca TressJoele Frank, Wilkinson Brimmer Katcher(212) 355-4449Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the closing of its previously announced non-brokered private placement for gross proceeds of $4,905,150 - consisting of $3,555,150 of Units and $1,350,000 of Debenture Units (each as defined below). The private placement consists of a combination of equity units (the 'Units') and convertible debenture units (the 'Debenture Units'), issued at a price of $0.05 per Unit and $50,000 per Debenture Unit. Each Unit includes one common share of the Company (a 'Common Share') and one Common Share purchase warrant (a 'Warrant'). Each Warrant entitles the holder to purchase one additional Common Share at a price of $0.10 for a period of 24 months following the date of issuance, subject to acceleration in certain scenarios and customary adjustments. Each Debenture Unit is comprised of one unsecured convertible debenture (a 'Debenture') in the principal amount of $50,000 and 100,000 Common Share purchase warrants (the 'Debenture Warrants'). Each Debenture Warrant will entitle the holder to purchase one additional Common Share at a price of $0.15 for a period of 24 months from issuance, subject to customary adjustments. The principal amount of each Debenture shall be repayable in 36 months from issuance (unless earlier converted or redeemed) and will accrue interest at a rate of 12% per annum. Until the principal amount is repaid, a Debenture holder shall have the option to convert the principal amount of the Debenture into Common Shares at a conversion price of $0.10 per Common Share, subject to customary adjustments, including adjustment upon completion of the proposed Consolidation (as defined below). Rakovina shall be entitled to redeem all or a portion of the principal amount of each Debenture at any time commencing 12 months after issuance of such Debenture, in cash and without premium. In connection with the private placement, Rakovina paid cash finder's fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., and Leede Financial Inc., totaling $ $60,035.50, and issued 1,200,710 non-transferable finder's warrants (each, a 'Finder's Warrant'). Each Finder's Warrant entitles the holder to purchase one Common Share at $0.10 for a period of 24 months, subject to acceleration on the same terms as the Warrants. Certain insiders of the Company subscribed for an aggregate of 14,700,000 Units for aggregate gross proceeds to the Company of $735,000. The issuance of such Units constitutes a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in special Transactions ('MI 61-101') and Policy 5.9 by the TSX Venture Exchange ('TSXV'). The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements under MI 61-101 on the basis that neither the fair market value of the Units issued to interested parties (as defined in MI 61-101), nor the consideration received for those Units, exceeds 25% of the Company's market capitalization. No new insiders were created, nor has there been a Change of Control (as defined in TSXV Policies) as a result of closing the private placement. The Company did not file a material change report more than 21 days before the closing date, as the details and amounts of insider participation was not finalized until shortly prior to the closing date. All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day in accordance with applicable securities laws. The Company previously announced it intends to implement a 10-for-1 share consolidation (the 'Consolidation') following closing of the private placement. The amounts set out above in respect of the private placement are all presented on a pre-Consolidation basis and will be adjusted following closing of the private placement upon completion of the Consolidation. The private placement and Consolidation are subject to final acceptance by the TSXV. 'We're pleased with the strong support from both existing and new shareholders,' said Jeff Bacha, Executive Chairman of Rakovina Therapeutics. 'This financing is a pivotal step in Rakovina's evolution. It not only provides the capital to advance our development plans but also strengthens our position as we align with prospective partners and U.S. investors for the next phase of growth.' Use of Proceeds Proceeds from the financing are intended to support Rakovina Therapeutics' growth across multiple fronts, including the continued integration of its proprietary next-generation AI-driven drug discovery tools, and the efforts to expand visibility among institutional investors in U.S. and global capital markets. IR and Marketing Collaborations Rakovina also announces the continued engagement of Fairfax Partners Inc. ('Fairfax') as its Investor Relations ('IR') partner and a new engagement of Machai Capital Inc. ('Machai') to provide corporate communication services. Fairfax will implement a comprehensive three-month IR program which will continue to build on Rakovina's market presence with a goal to increase its investor base. The program, which includes an option to renew, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. Under the terms of the agreement, Fairfax will receive an initial fee of $250,000 (plus GST), payable upon execution of the agreement. This amount will cover the first three months of marketing execution, with Fairfax retaining a 20% service fee on all marketing funds allocated. At its sole discretion, the Company may allocate up to an additional $200,000 to extend the campaign for an additional three-month term. Machai Capital will utilize its expertise in branding, content and data optimization, search engine optimization, search engine marketing, lead generation, digital marketing, social media marketing, email marketing, and brand marketing to enhance the Company's marketing campaigns and increase awareness of the Company. The Company will provide Machai Capital with a marketing budget of $250,000 (plus GST), payable upon entry into the agreement. As of the date hereof, the directors and officers of Machai Capital do not own any securities of the Company. Machai Capital and its principals have an arm's length relationship with the Company. About Machai Capital Machai Capital provides services in branding, content and data optimization, search engine optimization, search engine marketing, lead generation, digital marketing, social media marketing, email marketing, and brand marketing to enhance its client marketing campaigns and awareness. Machai Capital's head office is located in Vancouver, British Columbia. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed Consolidation, the use of proceeds from the private placement, the business plan of the company, the Company's growth across multiple fronts and other prospective statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed, except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact: Michelle Seltenrich, BSc, MBADirector, Corporate DevelopmentIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
